FDA
approval
· 2025-11-05
FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)
Summary
FDA approved a supplemental application for CONTRAVE EXTENDED-RELEASE (naltrexone hydrochloride and bupropion hydrochloride) by Nalpropion Pharmaceuticals LLC.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for CONTRAVE EXTENDED-RELEASE (NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE)